JP2003501087A - 腫瘍の治療のための組成物と方法 - Google Patents

腫瘍の治療のための組成物と方法

Info

Publication number
JP2003501087A
JP2003501087A JP2001502580A JP2001502580A JP2003501087A JP 2003501087 A JP2003501087 A JP 2003501087A JP 2001502580 A JP2001502580 A JP 2001502580A JP 2001502580 A JP2001502580 A JP 2001502580A JP 2003501087 A JP2003501087 A JP 2003501087A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
antibody
acid sequence
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001502580A
Other languages
English (en)
Japanese (ja)
Inventor
ボッツタイン，デーヴイッド，エー
ゴッダード，オードリー
ガーニー，オースティン，エル．
スミス，ヴィクトリア
ケー． ワタナベ，コリン，
ウッド，ウイリアム，アイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2003501087A publication Critical patent/JP2003501087A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001502580A 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法 Pending JP2003501087A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US13838599P 1999-06-09 1999-06-09
US60/138,385 1999-06-09
US14479099P 1999-07-20 1999-07-20
US60/144,790 1999-07-20
US14684399P 1999-08-03 1999-08-03
US60/146,843 1999-08-03
US14818899P 1999-08-10 1999-08-10
US60/148,188 1999-08-10
US14939699P 1999-08-17 1999-08-17
US14932799P 1999-08-17 1999-08-17
US14932099P 1999-08-17 1999-08-17
US60/149,396 1999-08-17
US60/149,320 1999-08-17
US60/149,327 1999-08-17
US15011499P 1999-08-20 1999-08-20
US60/150,114 1999-08-20
US15170099P 1999-08-31 1999-08-31
US15173499P 1999-08-31 1999-08-31
US60/151,734 1999-08-31
US60/151,700 1999-08-31
PCT/US2000/013358 WO2000075317A2 (en) 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2004186386A Division JP4252501B2 (ja) 1999-06-09 2004-06-24 腫瘍の治療のための組成物と方法
JP2005181534A Division JP4260778B2 (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Publications (1)

Publication Number Publication Date
JP2003501087A true JP2003501087A (ja) 2003-01-14

Family

ID=27581055

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2001502580A Pending JP2003501087A (ja) 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法
JP2004186386A Expired - Fee Related JP4252501B2 (ja) 1999-06-09 2004-06-24 腫瘍の治療のための組成物と方法
JP2005181588A Pending JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181558A Pending JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181534A Expired - Lifetime JP4260778B2 (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2004186386A Expired - Fee Related JP4252501B2 (ja) 1999-06-09 2004-06-24 腫瘍の治療のための組成物と方法
JP2005181588A Pending JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181558A Pending JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181534A Expired - Lifetime JP4260778B2 (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Country Status (8)

Country Link
EP (3) EP1657256B1 (https=)
JP (5) JP2003501087A (https=)
AT (2) ATE444971T1 (https=)
AU (1) AU4851900A (https=)
CA (1) CA2371434A1 (https=)
DE (2) DE60042799D1 (https=)
ES (2) ES2332916T3 (https=)
WO (1) WO2000075317A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
EP1235907A4 (en) * 1999-11-12 2003-07-30 Human Genome Sciences Inc 6 HUMAN, ELIMINATED PROTEINS
WO2001047957A2 (en) * 1999-12-29 2001-07-05 Zymogenetics, Inc. Human fgf-10- (kgf-2)-like protein zfgf-10
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
EP1366156A2 (en) * 2000-06-19 2003-12-03 F. Hoffmann-La Roche Ag Osteolevin gene polymorphisms
AU2003223214B2 (en) * 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
EP3712168A3 (en) 2011-12-28 2020-10-14 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
JP3399948B2 (ja) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Ｐ９０抗体またはプローブを用いた前癌細胞または癌細胞の検出方法
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
US5635370A (en) * 1994-04-08 1997-06-03 Yale University DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
EP0972022A2 (en) * 1997-01-21 2000-01-19 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
KR20050009764A (ko) * 1997-11-25 2005-01-25 제넨테크, 인크. 섬유아세포 성장 인자-19
EP1049708A4 (en) * 1998-01-23 2002-09-04 Human Genome Sciences Inc METH1 AND METH2 POLYNUCLEOTIDES AND POLYPEPTIDES
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Also Published As

Publication number Publication date
JP2006006331A (ja) 2006-01-12
JP4260778B2 (ja) 2009-04-30
EP1657256A3 (en) 2006-08-09
DE60042799D1 (de) 2009-10-01
AU4851900A (en) 2000-12-28
DE60043125D1 (de) 2009-11-19
ES2331657T3 (es) 2010-01-12
EP1683811B1 (en) 2009-08-19
ATE440109T1 (de) 2009-09-15
JP4252501B2 (ja) 2009-04-08
EP1185642A2 (en) 2002-03-13
ES2332916T3 (es) 2010-02-15
JP2006006332A (ja) 2006-01-12
WO2000075317A3 (en) 2001-02-08
ATE444971T1 (de) 2009-10-15
JP2005027667A (ja) 2005-02-03
JP2006006330A (ja) 2006-01-12
CA2371434A1 (en) 2000-12-14
WO2000075317A2 (en) 2000-12-14
EP1683811A3 (en) 2006-10-11
EP1657256B1 (en) 2009-10-07
EP1657256A2 (en) 2006-05-17
EP1683811A2 (en) 2006-07-26

Similar Documents

Publication Publication Date Title
EP1607402B1 (en) Method for the diagnosis of tumour
JP4252501B2 (ja) 腫瘍の治療のための組成物と方法
US20080175842A1 (en) Compositions and methods for treatment
JP2009000114A (ja) 腫瘍治療のための組成物及び方法
US20050176104A1 (en) Compositions and methods for the treatment of tumor
US20070026450A1 (en) Methods for the treatment of carcinoma
JP2003519491A (ja) 新規なｓｔｒａ６ポリペプチド
JP2006519774A (ja) 癌の治療のための組成物と方法
JP2003524380A (ja) 腫瘍治療のための組成物及び方法
JP2003524390A (ja) 腫瘍治療のための組成物及び方法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20031224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050523